Abstract Details

Title Social Support and Clinical Outcomes in Patients with Parkinson Disease After Deep Brain Stimulation

Topic Movement Disorders

Presentation(s) P2 - Poster Session 2 (11:45 AM-12:45 PM)

Poster/Presentation
Number 5-002

Objective

To evaluate perceived social support in Parkinson disease (PD) patients before and after deep brain stimulation (DBS) and its impact on clinical outcomes following DBS.

Background The social provisions scale (SPS) is a measure of a person’s perceived social support. We hypothesized that PD patients with good social support would have better outcomes following DBS than those with less robust social support.

Design/Methods This study included PD patients with motor fluctuations despite optimal medication management or severe rest tremor despite high levodopa doses who enrolled in our DBS database and completed subthalamic nucleus (STN) DBS surgery between 2010 and 2019 at our institution. 56 DBS patients (55 bilateral/1 unilateral) who completed the SPS before and 6-12 months after surgery were included in this analysis. Patients also completed the PDQ-39 and MDS-UPDRS Part I, II, III, and IV at each visit. Regression models evaluated the impact of the SPS baseline score on MDS-UPDRS and PDQ-39 scores as well as the impact of MDS-UPDRS scores on the SPS follow-up score.

Results DBS implantation significantly improved MDS-UPDRS I-IV and PDQ-39 scores. Perceived social support declined slightly after DBS (baseline SPS total score 82.55 ± 7.52 vs. follow-up SPS total score 78.83 ± 9.02, p=0.0001). Baseline SPS total score at baseline did not impact the MDS-UPDRS or PDQ-39 scores at follow-up. Additionally, the MDS-UPDRS scores at follow-up had no impact on SPS total score at follow-up.

Conclusions PD patients experienced a statistically significant decline in their total SPS score despite improvement in the MDS-UPDRS and PDQ-39 scores. Whether this decrease in perceived social support is clinically significant is yet to be determined.

Authors/Disclosures
Sydney M. Spagna, MD PRESENTER	Dr. Spagna has nothing to disclose.
	No disclosure on file
	No disclosure on file
Kelvin L. Chou, MD, FAAN (University of Michigan Health, Department of Neurology)	Dr. Chou has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Accordant. Dr. Chou has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Neurocrine. Dr. Chou has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbott. Dr. Chou has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cerevance. Dr. Chou has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Advarra. The institution of Dr. Chou has received research support from NIH. The institution of Dr. Chou has received research support from Parkinson Study Group. The institution of Dr. Chou has received research support from Michael J Fox Foundation. The institution of Dr. Chou has received research support from Cerevance. Dr. Chou has received publishing royalties from a publication relating to health care. Dr. Chou has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��